ACT34-CMI, bone marrow-derived cells for ischemic heart diseases
ACT34 are autologous CD34+ bone marrow-derived cells used to treat myocardial ischemia (MI). The CD34+ cells are injected back into the patients. ACT34-treated MI patients have reduced angina frequency and improved exercise tolerance, however cell mobilization and collection procedures are associated with elevation in cardiac enzyme levels.
Read More
Product Information for
ACT34-CMI, bone marrow-derived cells for ischemic heart diseases
Links related to the product - may include a range of information sources (e.g., press releases, websites, patents) related to the specific cell therapy application.
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access